Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

Purpose Despite advances in the treatment of colorectal cancer, third-line treatment options are still limited. Regorafenib was approved in 2012 for the treatment of patients with metastatic colorectal cancer previously treated with approved standard therapy. The purpose of this review is to present existing clinical data on regorafenib. Method We systematically searched the PubMed and Embase databases, as well as ASCO and ESMO conference...